Last reviewed · How we verify

Mometasone furoate 50 micrograms

Sanofi · Phase 3 active Small molecule

Mometasone furoate 50 micrograms is a Corticosteroid (glucocorticoid) Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Allergic rhinitis, Asthma, Chronic obstructive pulmonary disease (COPD). Also known as: NASONEX®.

Mometasone furoate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and reducing the production of inflammatory mediators.

Mometasone furoate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and reducing the production of inflammatory mediators. Used for Allergic rhinitis, Asthma, Chronic obstructive pulmonary disease (COPD).

At a glance

Generic nameMometasone furoate 50 micrograms
Also known asNASONEX®
SponsorSanofi
Drug classCorticosteroid (glucocorticoid)
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaImmunology / Inflammation
PhasePhase 3

Mechanism of action

Mometasone furoate is a potent synthetic glucocorticoid that exerts anti-inflammatory effects through activation of glucocorticoid receptors in target tissues. This leads to decreased production of pro-inflammatory cytokines, chemokines, and adhesion molecules, thereby reducing inflammation and immune cell infiltration. It is commonly used as a topical or inhaled agent for localized anti-inflammatory effects.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Mometasone furoate 50 micrograms

What is Mometasone furoate 50 micrograms?

Mometasone furoate 50 micrograms is a Corticosteroid (glucocorticoid) drug developed by Sanofi, indicated for Allergic rhinitis, Asthma, Chronic obstructive pulmonary disease (COPD).

How does Mometasone furoate 50 micrograms work?

Mometasone furoate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and reducing the production of inflammatory mediators.

What is Mometasone furoate 50 micrograms used for?

Mometasone furoate 50 micrograms is indicated for Allergic rhinitis, Asthma, Chronic obstructive pulmonary disease (COPD), Inflammatory skin conditions.

Who makes Mometasone furoate 50 micrograms?

Mometasone furoate 50 micrograms is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

Is Mometasone furoate 50 micrograms also known as anything else?

Mometasone furoate 50 micrograms is also known as NASONEX®.

What drug class is Mometasone furoate 50 micrograms in?

Mometasone furoate 50 micrograms belongs to the Corticosteroid (glucocorticoid) class. See all Corticosteroid (glucocorticoid) drugs at /class/corticosteroid-glucocorticoid.

What development phase is Mometasone furoate 50 micrograms in?

Mometasone furoate 50 micrograms is in Phase 3.

What are the side effects of Mometasone furoate 50 micrograms?

Common side effects of Mometasone furoate 50 micrograms include Headache, Pharyngitis, Epistaxis, Nasal irritation, Dysphonia, Oral candidiasis (with inhaled formulation).

What does Mometasone furoate 50 micrograms target?

Mometasone furoate 50 micrograms targets Glucocorticoid receptor and is a Corticosteroid (glucocorticoid).

Related